International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

S. Vincent Rajkumar, Meletios A. Dimopoulos, Antonio Palumbo, Joan Blade, Giampaolo Merlini, María Victoria Mateos, Shaji Kumar, Jens Hillengass, Efstathios Kastritis, Paul Richardson, Ola Landgren, Bruno Paiva, Angela Dispenzieri, Brendan Weiss, Xavier LeLeu, Sonja Zweegman, Sagar Lonial, Laura Rosinol, Elena Zamagni, Sundar JagannathOrhan Sezer, Sigurdur Y. Kristinsson, Jo Caers, Saad Z. Usmani, Juan José Lahuerta, Hans Erik Johnsen, Meral Beksac, Michele Cavo, Hartmut Goldschmidt, Evangelos Terpos, Robert A. Kyle, Kenneth C. Anderson, Brian G M Durie, Jesus F San Miguel

Research output: Contribution to journalArticle

Abstract

This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identification of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and radiographic variables that fulfil the criteria for the presence of myeloma-defining CRAB features, and the histological and monoclonal protein requirements for the disease diagnosis. Finally, we provide specific metrics that new biomarkers should meet for inclusion in the disease definition. The International Myeloma Working Group recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends that future studies analyse any differences in outcome that might occur as a result of the new disease definition.

Original languageEnglish
Pages (from-to)e538-e548
JournalThe Lancet Oncology
Volume15
Issue number12
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Multiple Myeloma
Biomarkers
Cytomegalovirus Infections
Hypercalcemia
Renal Insufficiency
Anemia
Clinical Trials
Bone and Bones
Proteins
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M. V., ... Miguel, J. F. S. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, 15(12), e538-e548. https://doi.org/10.1016/S1470-2045(14)70442-5

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. / Rajkumar, S. Vincent; Dimopoulos, Meletios A.; Palumbo, Antonio; Blade, Joan; Merlini, Giampaolo; Mateos, María Victoria; Kumar, Shaji; Hillengass, Jens; Kastritis, Efstathios; Richardson, Paul; Landgren, Ola; Paiva, Bruno; Dispenzieri, Angela; Weiss, Brendan; LeLeu, Xavier; Zweegman, Sonja; Lonial, Sagar; Rosinol, Laura; Zamagni, Elena; Jagannath, Sundar; Sezer, Orhan; Kristinsson, Sigurdur Y.; Caers, Jo; Usmani, Saad Z.; Lahuerta, Juan José; Johnsen, Hans Erik; Beksac, Meral; Cavo, Michele; Goldschmidt, Hartmut; Terpos, Evangelos; Kyle, Robert A.; Anderson, Kenneth C.; Durie, Brian G M; Miguel, Jesus F San.

In: The Lancet Oncology, Vol. 15, No. 12, 01.11.2014, p. e538-e548.

Research output: Contribution to journalArticle

Rajkumar, SV, Dimopoulos, MA, Palumbo, A, Blade, J, Merlini, G, Mateos, MV, Kumar, S, Hillengass, J, Kastritis, E, Richardson, P, Landgren, O, Paiva, B, Dispenzieri, A, Weiss, B, LeLeu, X, Zweegman, S, Lonial, S, Rosinol, L, Zamagni, E, Jagannath, S, Sezer, O, Kristinsson, SY, Caers, J, Usmani, SZ, Lahuerta, JJ, Johnsen, HE, Beksac, M, Cavo, M, Goldschmidt, H, Terpos, E, Kyle, RA, Anderson, KC, Durie, BGM & Miguel, JFS 2014, 'International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma', The Lancet Oncology, vol. 15, no. 12, pp. e538-e548. https://doi.org/10.1016/S1470-2045(14)70442-5
Rajkumar, S. Vincent ; Dimopoulos, Meletios A. ; Palumbo, Antonio ; Blade, Joan ; Merlini, Giampaolo ; Mateos, María Victoria ; Kumar, Shaji ; Hillengass, Jens ; Kastritis, Efstathios ; Richardson, Paul ; Landgren, Ola ; Paiva, Bruno ; Dispenzieri, Angela ; Weiss, Brendan ; LeLeu, Xavier ; Zweegman, Sonja ; Lonial, Sagar ; Rosinol, Laura ; Zamagni, Elena ; Jagannath, Sundar ; Sezer, Orhan ; Kristinsson, Sigurdur Y. ; Caers, Jo ; Usmani, Saad Z. ; Lahuerta, Juan José ; Johnsen, Hans Erik ; Beksac, Meral ; Cavo, Michele ; Goldschmidt, Hartmut ; Terpos, Evangelos ; Kyle, Robert A. ; Anderson, Kenneth C. ; Durie, Brian G M ; Miguel, Jesus F San. / International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. In: The Lancet Oncology. 2014 ; Vol. 15, No. 12. pp. e538-e548.
@article{d4baff0b93784f6aaed55fac953a6845,
title = "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma",
abstract = "This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identification of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and radiographic variables that fulfil the criteria for the presence of myeloma-defining CRAB features, and the histological and monoclonal protein requirements for the disease diagnosis. Finally, we provide specific metrics that new biomarkers should meet for inclusion in the disease definition. The International Myeloma Working Group recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends that future studies analyse any differences in outcome that might occur as a result of the new disease definition.",
author = "Rajkumar, {S. Vincent} and Dimopoulos, {Meletios A.} and Antonio Palumbo and Joan Blade and Giampaolo Merlini and Mateos, {Mar{\'i}a Victoria} and Shaji Kumar and Jens Hillengass and Efstathios Kastritis and Paul Richardson and Ola Landgren and Bruno Paiva and Angela Dispenzieri and Brendan Weiss and Xavier LeLeu and Sonja Zweegman and Sagar Lonial and Laura Rosinol and Elena Zamagni and Sundar Jagannath and Orhan Sezer and Kristinsson, {Sigurdur Y.} and Jo Caers and Usmani, {Saad Z.} and Lahuerta, {Juan Jos{\'e}} and Johnsen, {Hans Erik} and Meral Beksac and Michele Cavo and Hartmut Goldschmidt and Evangelos Terpos and Kyle, {Robert A.} and Anderson, {Kenneth C.} and Durie, {Brian G M} and Miguel, {Jesus F San}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/S1470-2045(14)70442-5",
language = "English",
volume = "15",
pages = "e538--e548",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "12",

}

TY - JOUR

T1 - International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

AU - Rajkumar, S. Vincent

AU - Dimopoulos, Meletios A.

AU - Palumbo, Antonio

AU - Blade, Joan

AU - Merlini, Giampaolo

AU - Mateos, María Victoria

AU - Kumar, Shaji

AU - Hillengass, Jens

AU - Kastritis, Efstathios

AU - Richardson, Paul

AU - Landgren, Ola

AU - Paiva, Bruno

AU - Dispenzieri, Angela

AU - Weiss, Brendan

AU - LeLeu, Xavier

AU - Zweegman, Sonja

AU - Lonial, Sagar

AU - Rosinol, Laura

AU - Zamagni, Elena

AU - Jagannath, Sundar

AU - Sezer, Orhan

AU - Kristinsson, Sigurdur Y.

AU - Caers, Jo

AU - Usmani, Saad Z.

AU - Lahuerta, Juan José

AU - Johnsen, Hans Erik

AU - Beksac, Meral

AU - Cavo, Michele

AU - Goldschmidt, Hartmut

AU - Terpos, Evangelos

AU - Kyle, Robert A.

AU - Anderson, Kenneth C.

AU - Durie, Brian G M

AU - Miguel, Jesus F San

PY - 2014/11/1

Y1 - 2014/11/1

N2 - This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identification of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and radiographic variables that fulfil the criteria for the presence of myeloma-defining CRAB features, and the histological and monoclonal protein requirements for the disease diagnosis. Finally, we provide specific metrics that new biomarkers should meet for inclusion in the disease definition. The International Myeloma Working Group recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends that future studies analyse any differences in outcome that might occur as a result of the new disease definition.

AB - This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identification of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and radiographic variables that fulfil the criteria for the presence of myeloma-defining CRAB features, and the histological and monoclonal protein requirements for the disease diagnosis. Finally, we provide specific metrics that new biomarkers should meet for inclusion in the disease definition. The International Myeloma Working Group recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends that future studies analyse any differences in outcome that might occur as a result of the new disease definition.

UR - http://www.scopus.com/inward/record.url?scp=84908604358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908604358&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(14)70442-5

DO - 10.1016/S1470-2045(14)70442-5

M3 - Article

C2 - 25439696

AN - SCOPUS:84908604358

VL - 15

SP - e538-e548

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 12

ER -